Natera Inc. (NTRA)

22.67
0.12 0.53
NASDAQ : Health Technology
Prev Close 22.79
Open 22.37
Day Low/High 22.36 / 22.95
52 Wk Low/High 11.08 / 29.62
Volume 197.64K
Avg Volume 712.30K
Exchange NASDAQ
Shares Outstanding 69.60M
Market Cap 1.58B
EPS -2.20
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Signatera™ Blood Test Detects Bladder Cancer Relapse Up To Eight Months Earlier Than Current Clinical Standards

Signatera™ Blood Test Detects Bladder Cancer Relapse Up To Eight Months Earlier Than Current Clinical Standards

Journal of Clinical Oncology Study Shows Natera's Test is Highly Prognostic and Effective for Recurrence Detection

FDA Grants Breakthrough Device Designation To Natera's Signatera Test

FDA Grants Breakthrough Device Designation To Natera's Signatera Test

Accelerated Regulatory Review Intended to Expedite Use of Test in Pharmaceutical Trials and Improve Upon Current Clinical Standards

Natera Announces First Quarter 2019 Earnings Conference Call

Natera Announces First Quarter 2019 Earnings Conference Call

SAN CARLOS, Calif., May 2, 2019 /PRNewswire/ --  Natera, Inc.

Natera Announces Pricing Of Follow-On Offering

Natera Announces Pricing Of Follow-On Offering

SAN CARLOS, Calif., April 17, 2019 /PRNewswire/ -- Natera, Inc.

Natera Launches Proposed Follow-On Offering

Natera Launches Proposed Follow-On Offering

SAN CARLOS, Calif., April 16, 2019 /PRNewswire/ --  Natera, Inc.

New Publication Validates Clinical Performance Of Signatera For Recurrence Monitoring And MRD Assessment In Breast Cancer

New Publication Validates Clinical Performance Of Signatera For Recurrence Monitoring And MRD Assessment In Breast Cancer

Molecular Residual Disease Detected Up to Two Years Prior to Clinical Relapse, with Zero False Positives

Natera Announces Plans To Commercialize Tumor Whole Exome Sequencing From Plasma

Natera Announces Plans To Commercialize Tumor Whole Exome Sequencing From Plasma

Represents Next Advancement in Company's Innovative Oncology ctDNA Program

Medicare Issues Draft Local Coverage Determination For Natera's New Prospera™ Kidney Transplant Rejection Test

Medicare Issues Draft Local Coverage Determination For Natera's New Prospera™ Kidney Transplant Rejection Test

Represents Major Reimbursement Milestone on Company's Path to Commercialization in 2019

Natera To Partner With AMAL Therapeutics On Clinical Trial Using Signatera MRD Test To Assess Treatment Response To Colorectal Cancer Vaccine

Natera To Partner With AMAL Therapeutics On Clinical Trial Using Signatera MRD Test To Assess Treatment Response To Colorectal Cancer Vaccine

New Clinical Trial Adds to Growing Number of Studies Supporting Use of Signatera as a Potential Surrogate Endpoint

Natera Reports Fourth Quarter And Fiscal Year 2018 Financial Results

Natera Reports Fourth Quarter And Fiscal Year 2018 Financial Results

SAN CARLOS, Calif., March 12, 2019 /PRNewswire/ --  Natera, Inc.

Natera And BGI Genomics Announce $50M Partnership To Commercialize Signatera Oncology Test In China And To Develop Reproductive Health Tests In Select Markets On BGI's DNBseq™ Technology Platform

Natera And BGI Genomics Announce $50M Partnership To Commercialize Signatera Oncology Test In China And To Develop Reproductive Health Tests In Select Markets On BGI's DNBseq™ Technology Platform

Partnership marks significant milestone for Natera in monetizing its Signatera MRD test and for BGI Genomics a strong endorsement of its DNBseq™ technology platform by a leader in cell-free DNA genetic testing

Natera, Inc. Announces Fourth Quarter And Fiscal 2018 Earnings Conference Call

Natera, Inc. Announces Fourth Quarter And Fiscal 2018 Earnings Conference Call

Natera Also to Present at 39th Annual Cowen Healthcare Conference

Natera Announces Publication Of Analytical Validation Study Demonstrating Superior Precision Of Its Kidney Transplant Rejection Assay

Natera Announces Publication Of Analytical Validation Study Demonstrating Superior Precision Of Its Kidney Transplant Rejection Assay

Core Technology Delivers Superior Analytical Performance, Underpins Outstanding Clinical Performance

Natera Presents Outcomes Data At SMFM Annual Meeting Showing Strong Clinical Performance Of Its SNP-Based Non-Invasive Prenatal Test

Natera Presents Outcomes Data At SMFM Annual Meeting Showing Strong Clinical Performance Of Its SNP-Based Non-Invasive Prenatal Test

Study Shows High Positive Predictive Values in Detecting Common Chromosomal Aneuploidies in All Women, Including Women Under 35 Years of Age

Natera Announces Agreement With One Lambda To Co-Distribute Its Kidney Transplant Rejection Test

Natera Announces Agreement With One Lambda To Co-Distribute Its Kidney Transplant Rejection Test

Agreement Enhances Commercial Presence in Organ Transplant Centers

Natera Announces Publication Of Kidney Transplant Validation Study, Demonstrating Superior Data In Detection Of Clinical And Subclinical Rejection

Natera Announces Publication Of Kidney Transplant Validation Study, Demonstrating Superior Data In Detection Of Clinical And Subclinical Rejection

Represents Successful Achievement of All 2018 Commercialization Milestones, on Path to 2019 Launch

Natera Obtains Z-Codes For Signatera MRD And Treatment Monitoring Test In Oncology

Natera Obtains Z-Codes For Signatera MRD And Treatment Monitoring Test In Oncology

Represents Key Reimbursement Milestone In Line with Planned Clinical Launch

Natera Appoints Steve Chapman CEO And Robert Schueren COO; Matthew Rabinowitz Moves To Executive Chairman

Natera Appoints Steve Chapman CEO And Robert Schueren COO; Matthew Rabinowitz Moves To Executive Chairman

Proven Commercial Execution Selected for CEO Role; Seasoned Operational Expertise Selected for COO Role

Natera Becomes Oversold (NTRA)

Natera Becomes Oversold (NTRA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Natera Achieves Enrollment Goal Of 20,000 Patients In SMART Study

Natera Achieves Enrollment Goal Of 20,000 Patients In SMART Study

Primary study results on the 20,000 patients anticipated in 2019 to validate the clinical utility of routine screening for microdeletion genetic conditions

Natera Receives Unique Z-Code For Its Kidney Transplant Rejection Monitoring Test

Natera Receives Unique Z-Code For Its Kidney Transplant Rejection Monitoring Test

Represents a Key Milestone Towards Achieving Medicare Reimbursement

Interesting NTRA Put And Call Options For July 2019

Interesting NTRA Put And Call Options For July 2019

Investors in Natera Inc saw new options become available this week, for the July 2019 expiration. One of the key data points that goes into the price an option buyer is willing to pay, is the time value, so with 240 days until expiration the newly available contracts represent a potential opportunity for sellers of puts or calls to achieve a higher premium than would be available for the contracts with a closer expiration.

Natera Is Now Oversold (NTRA)

Natera Is Now Oversold (NTRA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Natera Is Now Oversold (NTRA)

Natera Is Now Oversold (NTRA)

Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which measures momentum on a scale of zero to 100.

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: ATRO, IDT Downgrades: ALGT, AMSWA, AMWD, ETSY, JBL, MMYT, NTRA, TAL, TDOC, UCTT Initiations: YUMA Read on to get TheStreet Quant Ratings' detailed report:

Ratings Changes Today

TheStreet Quant Ratings provides fair and objective information to help you make educated investing decisions. We rate over 4,100 stocks daily and provide 5-page PDF reports for each stock. These ratings can change daily and today's changes are reflected in the email below. If you are looking to check-up on the stocks you currently own or are looking for new ideas, you can find our full database of password-protected ratings reports in our proprietary ratings screener: http://www.thestreet.com/k/qr/flat/stock-screener.html Upgrades: AVT, CROX, CYBR, EGRX, GWRS, HSTM, LITE, NRP, NTRA, OSUR, SITE, USM Downgrades: AAXN, BDGE, BPFH, MCHP, ORA, QEP, SJI Initiations: None Read on to get TheStreet Quant Ratings' detailed report:

TheStreet Quant Rating: D (Sell)